Krystal Biotech (NASDAQ:KRYS) Announces Quarterly Earnings Results

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings results on Tuesday. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08, FiscalAI reports. The firm had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%.

Here are the key takeaways from Krystal Biotech’s conference call:

• Krystal reported Q4 net VYJUVEK revenue of $107.1M, >$730M lifetime sales, a 94% gross margin, and $955.9M in cash and investments, providing strong runway for global launches and pipeline execution.
• Clinical momentum accelerated — KB-407 showed successful lung delivery and full‑length CFTR expression (transduction 29–42%), repeat‑dosing is expected in H1 2026, and the company expects multiple registrational readouts (KB801/KB803/KB408) and RMAT/Fast Track–designated programs to report data before year‑end.
• Guidance for 2026 non‑GAAP R&D and SG&A of $175–$195M (up from $150.3M in 2025) and higher Q4 SG&A reflect increased launch and staffing costs, which could pressure near‑term profitability despite one‑time tax benefits that boosted reported EPS.
• Reimbursement and timing risks remain — Germany pricing talks are expected to extend into H2 2026, France likely into 2027, and accruals/timing mean revenue may not scale linearly with patient counts; Japan’s initial two‑week prescription rule could temporarily depress early compliance.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $283.29 on Thursday. The company has a 50-day simple moving average of $264.84 and a two-hundred day simple moving average of $208.40. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $298.30. The stock has a market capitalization of $8.22 billion, a PE ratio of 41.36 and a beta of 0.49.

Key Headlines Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 earnings beat and commercial traction: KRYS reported Q4 EPS above estimates and Vyjuvek U.S. sales rose (~17%), while management cited expanded payer coverage (660+ U.S. reimbursements) and pipeline progress — fundamentals that support revenue growth and margin outlooks. Zacks: Q4 Earnings Beat
• Positive Sentiment: Analyst reiterations/upgrades lift sentiment: Chardan raised its price target to $323 (buy) and HC Wainwright maintains a Buy with a $310 target and updated Q1 EPS estimate — analyst support can push demand for momentum names. The Fly: Price Target Raise MarketBeat: HC Wainwright Note
• Positive Sentiment: Market reaction — gap up / new 12‑month high: Multiple outlets report KRYS gapped up and hit a new 12‑month high after the results, reflecting bullish momentum from the beat and upgraded outlooks. American Banking News: New 12‑Month High
• Positive Sentiment: Global rollout and margin guidance: Management flagged plans to expand VYJUVEK into Italy in H2 2026 and reiterated a high gross‑margin profile (90–95%), supporting long‑term profitability assumptions. MSN: Global Expansion
• Neutral Sentiment: Pipeline progress and narrative shift: Analysts and trade commentary are re‑framing KRYS from a single‑product commercial story to one that includes gene‑therapy (KB707) and oncology angles, which increases upside potential but also adds development risk and timeline uncertainty. Yahoo Finance: Reassessing KRYS
• Neutral Sentiment: Full earnings materials available: Investors can review the earnings‑call transcript and presentation for guidance/detail on uptake, reimbursement dynamics, and pipeline milestones to refine models. Seeking Alpha: Call Transcript Presentation
• Negative Sentiment: Short‑term profit‑taking and volatility: Despite the beat, some reports note intraday declines (~2% slips) as investors locked gains after a strong 1‑year rally; high valuation (P/E ~41) and concentrated upside expectations raise sensitivity to execution misses. Investing.com: Shares Slip

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the transaction, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in the company. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth $34,000. UMB Bank n.a. grew its stake in Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares in the last quarter. Global Retirement Partners LLC increased its holdings in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the period. Danske Bank A S purchased a new stake in Krystal Biotech in the third quarter worth about $35,000. Finally, Wilmington Savings Fund Society FSB boosted its stake in shares of Krystal Biotech by 78.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 393 shares of the company’s stock valued at $69,000 after purchasing an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. The Goldman Sachs Group raised their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Citigroup raised their target price on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research note on Wednesday. Chardan Capital boosted their price target on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Finally, Zacks Research downgraded Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $307.22.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.